Drug intelligence / Profile preview

BCMA-UCART

Development stage: Phase 1
Lead developer: BRL Medicine
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BCMA-UCART is an allogeneic CAR-T cell therapy designed to treat relapsed or refractory multiple myeloma. It is developed using T cells from healthy donors, which are genetically engineered to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), a protein highly expressed on multiple myeloma cells. The therapy aims to enable these modified T cells to recognize and kill BCMA-expressing tumor cells in patients. Prior to infusion, patients typically receive conditioning chemotherapy with cyclophosphamide and fludarabine. BCMA-UCART represents a universal CAR-T approach, as opposed to autologous therapies that use the patient’s own T cells[1][2][5].

Other names: BCMA-UCART

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on BCMA-UCART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCMA-UCART.

Explore the full profile